Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 107 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Genetics Hypertension Clear all

Conditions: Sickle Cell Disease
Interventions: Cardiac magnetic resonance imaging (CMR); Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Sickle Cell Disease, Pulmonary Hypertension
Interventions: Hydroxyurea; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 10 Years to 25 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sickle Cell Disease, Obesity, Childhood, Hypertension, Hyperlipidemia in Children, Hyperglycemia
Interventions: Not listed
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 10 Years to 19 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Hypertension
Interventions: Para-aminohippuric Acid, Angiotensin II, Norepinephrine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions: Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™, STEEN Solution™; Procedure · Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 15 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions: Not listed
Lead sponsor: Global Healthy Living Foundation; Other
Eligibility: 19 Years and older
Enrollment: 40,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Upper Nyack, New York

Conditions: Cardiovascular Disease (CVD), Heart Failure, Aortic Stenosis, Aortic Stenosis Disease, Hypertension, Hypertension (HTN), Hypertrophic Cardiomyopathy Patients, Hypertrophic Cardiomyopathy Without Obstruction, Hypertrophic Cardiomyopathy, Obstructive, Dilated Cardiomyopathy (DCM), Dilated Cardiomyopathy, Dilated Cardiomyopathy, Familial
Interventions: Not listed
Lead sponsor: Prolaio; Industry
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Persistent Pulmonary Hypertension of the Newborn
Interventions: Not listed
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Up to 12 Months
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hypertension
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Amplification, FGFR2 Gene Short Variants, FGFR3 Gene Fusion/Rearrangement, FGFR3 Gene Amplification, FGFR3 Gene Short Variants, FGFR2 Genetic Alterations, FGFR3 Genetic Alterations, Advanced Solid Tumors
Interventions: CGT4859; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 12
States / cities: Palo Alto, California • Jacksonville, Florida • Tampa, Florida + 9 more

Conditions: Metabolic Syndrome
Interventions: ELM Group, ELM Classes, ELM Individual; Behavioral · Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 72 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chuvash Polycythemia, Cerebrovascular Disease, Pulmonary Hypertension, Sickle Cell Anemia
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 3 Years to 20 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Bethesda, Maryland + 2 more

Conditions: Aniridia, Eye Abnormality, Ocular Hypertension, Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1977 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension Associated With Connective Tissue Disease, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder), Pulmonary Arterial Hypertension of Congenital Heart Disease, Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension
Interventions: Saliva sample, Health surveys; Genetic · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Glaucoma
Interventions: Cosopt (combination eyedrop of dorzolamide and timolol); Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 99 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hypertension, Atherosclerotic Cardiovascular Disease
Interventions: Regular Care, SBP PRS Dissemination; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 55 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hypertension
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 3 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Orange, Connecticut

Conditions: Optic Neuropathy
Interventions: magnetic resonance image (MRI), Optical Coherence Tomography (OCT); Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Thyroid Eye Disease, Ocular Hypertension, Glaucoma
Interventions: Prostaglandin Analog, Timolol; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Primary Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: Wills Eye; Other
Eligibility: 40 Years and older
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
Interventions: Hyperpolarized Xe129; Drug
Lead sponsor: Mario Castro, MD, MPH; Other
Eligibility: 3 Years and older
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Pseudotumor Cerebri, Cystinosis
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 2 Years to 50 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension, Genetics Hypertension
Interventions: Eplerenone vs Amlodipine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Kidney Disease, Hypertension
Interventions: Timing of return of results; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 6,789 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 14
States / cities: Birmingham, Alabama • Gainesville, Florida • Jacksonville, Florida + 7 more

Search by objective public record fields.

Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease

Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension

Obesity in Pediatric Sickle Cell Disease: A New Phenomenon

Genetic Mechanisms in Human Hypertension

Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability

PatientSpot Formerly Known as ArthritisPower

Study of the Progression of Chronic Cardiovascular Conditions

PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn

Genetic Analysis of African-Americans With High Blood Pressure

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

A Pilot Study of a Lifestyle Intervention on the Metabolic Syndrome (3ELM Study)

Pulmonary Hypertension, Hypoxia and Sickle Cell Disease

Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and Lens

Rutgers University Study of the Genetics of Pulmonary Hypertension

Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions

Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure

Intergenerational Blood Pressure Study

Biomechanics of Optic Neuropathy

The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.

How Does Your Genetic Make-up (Profile) Influence Your Glaucoma?

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study

Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN

Genetic Testing to Understand and Address Renal Disease Disparities Across the United States